Clinical Trial Detail

NCT ID NCT03595917
Title ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Marlise R. Luskin
Indications

chronic myeloid leukemia

childhood B-cell acute lymphoblastic leukemia

Therapies

Asciminib + Dasatinib + Prednisone

Age Groups: adult senior

No variant requirements are available.